The results of vaccination against novel coronavirus infection in adolescents with allergic diseases

Novel coronavirus infection requires analyzing its course in patients with allergic diseases. Patients with atopic allergic diseases remain insufficiently studied with regard to the peculiarities of the course of both the underlying allergic disease and infectious processes caused by viruses and bacteria. Epithelial cells in bronchial asthma do not respond sufficiently to interferons, suggesting that SARS-CoV-2 infection may suppress spontaneous upregulation of angiotensin-converting enzyme expression, which ultimately reduces disease severity, but at the same time makes patients with allergic atopic diseases susceptible to other viral infections. The results obtained indicate statistically significant differences in the formation of anti-RBD IgG antibodies to SARS-CoV-2 between the group of adolescents with bronchial asthma vaccinated against a new coronavirus infection and those not vaccinated against it. During the follow-up period after 6 months, a statistically significant increase in anti-RBD IgG titer to SARS-CoV-2 due to novel coronavirus infection was observed among the unimmunized children. Clinical parameters indicated a favorable course of atopic process and control of bronchial asthma exacerbations in adolescents who received vaccination against both new coronavirus infection and influenza, while those who did not receive vaccination against these viral infections had bronchial asthma exacerbations due to respiratory infection. Also among patients with bronchial asthma who received influenza vaccination, there were no cases of influenza A and bronchial asthma exacerbations due to respiratory infections. In this regard, influenza vaccination is an important intervention to maintain control of asthma exacerbations. It is noteworthy that no new coronavirus infection was reported among vaccinated adolescents within a year after immunization. At the same time, 6 months after vaccination against a new coronavirus infection, we observed a statistically significant increase in antibody levels in unvaccinated adolescents, indicating the presence of high viral neutralizing activity. Vaccination against novel coronavirus infection in patients with bronchial asthma may be considered a possibility.

Authors

Institutions

Publication Details

Journal
Russian Journal of Immunology
Published
2024-10-25
DOI
https://doi.org/10.46235/1028-7221-16755-tro
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The results of vaccination against novel coronavirus infection in adolescents with allergic diseases

N. P. Andreeva
Russian Journal of Immunology
Asthma and respiratory diseases
article

The results of vaccination against novel coronavirus infection in adolescents with allergic diseases

N. P. Andreeva
article en

Abstract

Novel coronavirus infection requires analyzing its course in patients with allergic diseases. Patients with atopic allergic diseases remain insufficiently studied with regard to the peculiarities of the course of both the underlying allergic disease and infectious processes caused by viruses and bacteria. Epithelial cells in bronchial asthma do not respond sufficiently to interferons, suggesting that SARS-CoV-2 infection may suppress spontaneous upregulation of angiotensin-converting enzyme expression, which ultimately reduces disease severity, but at the same time makes patients with allergic atopic diseases susceptible to other viral infections. The results obtained indicate statistically significant differences in the formation of anti-RBD IgG antibodies to SARS-CoV-2 between the group of adolescents with bronchial asthma vaccinated against a new coronavirus infection and those not vaccinated against it. During the follow-up period after 6 months, a statistically significant increase in anti-RBD IgG titer to SARS-CoV-2 due to novel coronavirus infection was observed among the unimmunized children. Clinical parameters indicated a favorable course of atopic process and control of bronchial asthma exacerbations in adolescents who received vaccination against both new coronavirus infection and influenza, while those who did not receive vaccination against these viral infections had bronchial asthma exacerbations due to respiratory infection. Also among patients with bronchial asthma who received influenza vaccination, there were no cases of influenza A and bronchial asthma exacerbations due to respiratory infections. In this regard, influenza vaccination is an important intervention to maintain control of asthma exacerbations. It is noteworthy that no new coronavirus infection was reported among vaccinated adolescents within a year after immunization. At the same time, 6 months after vaccination against a new coronavirus infection, we observed a statistically significant increase in antibody levels in unvaccinated adolescents, indicating the presence of high viral neutralizing activity. Vaccination against novel coronavirus infection in patients with bronchial asthma may be considered a possibility.

Russian Journal of ImmunologyVol. 27(4)
Chuvash State University (RU)
Good health and well-being
Openalex Percentile: Top 74%
Asthma and respiratory diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.